SCORES is a phase Ib/II trial of Durvalumab (a PD-L1 inhibitor) in combination with either AZD9150 or AZD5069 in advanced solid tumors including recurrent / metastatic HNSCC (NCT02499328). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.